Kausikk Ray News Today

Unlike statins, bempedoic acid was not associated with an increased risk of new-onset diabetes, even in those on the cusp.

Study investigators offered updated data from 2 key trials presented in the past year: CLEAR Outcomes in low-density lipoprotein cholesterol and OCEAN(a)-DOSE in lipoprotein (a).

– In total cardiovascular event analysis, bempedoic acid shows20% risk reductionin MACE-4 and 17% risk reduction in MACE-3–

– In total cardiovascular event analysis, bempedoic acid shows 20% risk reduction in MACE-4 and 17% risk reduction in MACE-3 – – In an analysis of...

– Q2 U.S. Net Product Revenue Grew 49% Y/Y to $20.3 Million – – Q2 Retail Prescription Equivalents Grew 26% Y/Y; Q2 New to Brand Prescriptions Grew 28% Q/Q – – Submitted Applications for...

According to new research, patients who were unable to tolerate statins showed reduced cardiovascular events after taking bempedoic acid.

The National Lipid Association Scientific Sessions will be held today to Sunday and will spotlight statements on nutrition in adults with dyslipidemia, include sessions on the integration of lipid guidelines in clinical practice and more.Healio | Cardiology Today spoke with NLA President Kevin C. Maki, PhD, CLS, FNLA, FTOS, FACN, chief scientist at Midwest Biomedical Research and adjunct

Treating younger patients with a 10-year risk less than 10% is more likely to prevent CVD before it’s too late, experts said.

Results from a crossover subgroup of 92 patients in ORION-3 documented evolocumabs greater LDL-lowering efficacy compared with inclisiran.

LDL-C stayed down for 4 years and so did PCSK9 levels, but the real test for inclisiran will be the ongoing CV outcomes studies.